Metal-interferon-alpha crystals
    2.
    发明授权
    Metal-interferon-alpha crystals 失效
    金属 - 干扰素α晶体

    公开(公告)号:US5441734A

    公开(公告)日:1995-08-15

    申请号:US24330

    申请日:1993-02-25

    摘要: The present invention provides for crystalline zinc-interferon alfa-2 (IFN .alpha.-2) having a monoclinic morphology. The present invention further provides for crystalline cobalt-IFN .alpha.-2, crystalline calcium-IFN .alpha.-2, and crystalline IFN .alpha.-2 having a serum half-life of at least about 12 hours when injected into a primate. The present invention further provides for a method for producing a crystalline IFN .alpha.-2 comprising forming a soluble metal-IFN .alpha.-2 complex, and equilibrating the soluble metal-IFN .alpha.-2 complex in solution with an acetate salt of the metal under conditions that will cause the metal-IFN .alpha.-2 solution to become supersaturated and form crystalline metal-IFN .alpha.-2. The present invention also includes crystalline metal-alfa interferon having monoclinic, plate and needle morphologies.

    摘要翻译: 本发明提供具有单斜晶形的结晶性锌 - 干扰素α-2(IFNα-2)。 本发明还提供了当注射到灵长类动物中时,具有至少约12小时的血清半衰期的结晶钴-IFFα-2,结晶性钙-IFNα2和结晶IFNα-2。 本发明进一步提供了一种用于产生结晶IFNα-2的方法,包括形成可溶性金属-IFMα-2复合物,并在条件下用金属的乙酸盐平衡溶液中的可溶性金属-IFMα-2复合物 这将导致金属-IFNα-2溶液变得过饱和并形成结晶金属-IFNα-2。 本发明还包括具有单斜晶系,板和针形态的结晶金属-α干扰素。